252 related articles for article (PubMed ID: 18650151)
1. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
Conlin AK; Seidman AD
Clin Breast Cancer; 2008 Jun; 8(3):215-23. PubMed ID: 18650151
[TBL] [Abstract][Full Text] [Related]
2. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe.
Gao S; Barber B; Schabert V; Ferrufino C
Curr Med Res Opin; 2012 Jul; 28(7):1111-8. PubMed ID: 22587480
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
4. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
5. First-line chemotherapy for metastatic breast cancer.
Telli ML; Carlson RW
Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S66-72. PubMed ID: 19596645
[TBL] [Abstract][Full Text] [Related]
6. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R
Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
[TBL] [Abstract][Full Text] [Related]
8. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
Damasceno M
Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
11. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
Greenberg S; Rugo HS
Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
[TBL] [Abstract][Full Text] [Related]
12. HER2 and response to paclitaxel in node-positive breast cancer.
Hayes DF; Thor AD; Dressler LG; Weaver D; Edgerton S; Cowan D; Broadwater G; Goldstein LJ; Martino S; Ingle JN; Henderson IC; Norton L; Winer EP; Hudis CA; Ellis MJ; Berry DA;
N Engl J Med; 2007 Oct; 357(15):1496-506. PubMed ID: 17928597
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
Paplomata E; Nahta R; O'Regan RM
Cancer; 2015 Feb; 121(4):517-26. PubMed ID: 25346473
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
Curigliano G; Viale G; Bagnardi V; Fumagalli L; Locatelli M; Rotmensz N; Ghisini R; Colleoni M; Munzone E; Veronesi P; Zurrida S; Nolè F; Goldhirsch A
J Clin Oncol; 2009 Dec; 27(34):5693-9. PubMed ID: 19884553
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
[TBL] [Abstract][Full Text] [Related]
17. Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey.
DeKoven M; Bonthapally V; Jiao X; Ganguli A; Pathak P; Lee WC; Ray S
J Comp Eff Res; 2012 Sep; 1(5):453-63. PubMed ID: 24236422
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
19. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Gligorov J; Lotz JP
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
[TBL] [Abstract][Full Text] [Related]
20. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
Tkaczuk KH
Clin Ther; 2009; 31 Pt 2():2273-89. PubMed ID: 20110041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
